Edetate Disodium-Based Treatment for Secondary Prevention in Post-Myocardial Infarction Patients.

Gervasio A Lamas, Omar M Issa

Journal: Current cardiology reports 2016;18(2):20

PMID: 26797807

Abstract

An abundance of data, known for decades, is available linking metals, such as lead and cadmium, with cardiovascular disease. However, the idea that these toxic metals could be a modifiable risk factor for atherosclerosis did not become apparent clinically until the completion of the Trial to Assess Chelation Therapy in 2012. This pivotal study was the first double-blind, randomized, controlled trial of its kind to demonstrate a clear improvement in cardiovascular outcomes with edetate disodium therapy in a secondary prevention, post-myocardial infarction population. This effect size was most striking in diabetic patients, where the efficacy of edetate disodium was comparable, if not superior, to that of current guideline-based therapies. Given the economic burden of diabetes and cardiovascular disease, the potential impact of this therapy could be enormous if the results of this study are replicated.

Address: Columbia University Division of Cardiology, Mount Sinai Medical Center, Miami Beach FL, 4300 Alton Road, Miami Beach, FL, 33140, USA. [email protected].; Columbia University Division of Cardiology, Mount Sinai Medical Center, Miami Beach FL, 4300 Alton Road, Miami Beach, FL, 33140, USA.

DOI: 10.1007/s11886-015-0690-9

Link outs

Free resources

Medical:

https://medlineplus.gov/heartattack.html

Other Literature Sources:

https://scite.ai/reports/26797807

Subscription / membership required

Full Text Sources:

https://dx.doi.org/10.1007/s11886-015-0690-9

MeSH Terms: Atherosclerosis, Calcium Chelating Agents, Chelation Therapy, Dose-Response Relationship, Drug, Double-Blind Method, Edetic Acid, Heavy Metal Poisoning, Humans, Metals, Heavy, Myocardial Infarction, Poisoning, Risk Factors, Secondary Prevention, Survivors, Treatment Outcome